<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Definition and staging of chronic kidney disease in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Definition and staging of chronic kidney disease in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Definition and staging of chronic kidney disease in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew S Levey, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lesley A Inker, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary C Curhan, MD, ScD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H27258226"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The definition and classification of chronic kidney disease (CKD) guidelines were introduced by the National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative (KDOQI) in 2002, and were subsequently adopted with minor modifications by the international guideline group Kidney Disease Improving Global Outcomes (KDIGO) in 2004 [<a href="#rid1">1-3</a>].</p><p>These CKD guidelines shifted the concept of kidney disease from that of an uncommon life-threatening condition requiring care by nephrologists to that of a common condition with a range of severity meriting attention by general internists, and demanding strategies for prevention, early detection, and management [<a href="#rid4">4,5</a>]. The guidelines had a major effect on clinical practice, research, and public health, but also generated substantial controversy [<a href="#rid6">6-11</a>].</p><p>The most recent definition and classification of CKD will be addressed here. Discussions pertaining to the assessment of kidney function, the epidemiology of CKD, screening for CKD, evaluation of patients with CKD, overview of the management of CKD, and the association between CKD and cardiovascular disease are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7236.html" rel="external">"Epidemiology of chronic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15768.html" rel="external">"Early detection of chronic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7188.html" rel="external">"Diagnostic approach to adult patients with subacute kidney injury in an outpatient setting"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease"</a>.)</p><p></p><p class="headingAnchor" id="H1054473"><span class="h1">CONTROVERSIES ADDRESSED BY THE GUIDELINES</span><span class="headingEndMark"> — </span>In 2009, Kidney Disease: Improving Global Outcomes (KDIGO) convened a Controversies Conference to address key areas of controversy and review data on more than 1.5 million individuals from 45 cohorts that was assembled by the CKD Prognosis Consortium [<a href="#rid12">12-16</a>]. The following controversies were among those discussed:</p><p class="bulletIndent1"><span class="glyph">●</span>Should the albuminuria threshold to define CKD continue to be 30 mg/day (or equivalent)?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Should the glomerular filtration rate (GFR) threshold to define CKD continue to be 60 mL/min per 1.73 m<sup>2</sup>?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Should the GFR threshold used to define CKD depend upon age?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Should patients diagnosed as having CKD be staged based upon albuminuria in addition to GFR?</p><p></p><p>Conference attendees recommended, by at least a two-thirds majority vote, that the previous Kidney Disease Outcomes Quality Initiative (KDOQI) and KDIGO definitions of CKD be retained, but that the classification be modified to include the cause of disease and albuminuria staging [<a href="#rid12">12</a>]. KDIGO subsequently updated the guidelines in 2012 and adopted the recommendations [<a href="#rid17">17</a>]. The rationale behind these decisions is discussed in the sections that follow.</p><p class="headingAnchor" id="H27258404"><span class="h1">DEFINITION AND STAGING OF CHRONIC KIDNEY DISEASE</span></p><p class="headingAnchor" id="H27258373"><span class="h2">Framework and conceptual model</span><span class="headingEndMark"> — </span>We agree with Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) that CKD is a heterogeneous group of disorders characterized by alterations in kidney structure and function, which manifest in various ways depending upon the underlying cause or causes and the severity of disease  (<a class="graphic graphic_figure graphicRef77385" href="/d/graphic/77385.html" rel="external">figure 1</a>) [<a href="#rid1">1,4</a>]. Risk factors for CKD include genetic or sociodemographic predisposition, or the presence of diseases which can initiate and propagate kidney disease. Kidney failure is the end-stage of CKD and is defined as severely reduced kidney function or treatment with dialysis. The term "end-stage kidney disease" (ESKD) generally refers to chronic kidney failure treated with either dialysis or transplantation. Acute kidney injury (AKI) may complicate CKD and hasten its progression [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Natural history of kidney disease'</a> and  <a class="medical medical_review" href="/d/html/7238.html" rel="external">"Definition and staging criteria of acute kidney injury in adults"</a>.)</p><p>CKD is usually asymptomatic in its early stages. Symptoms appear in later stages in association with complications  (<a class="graphic graphic_figure graphicRef77385" href="/d/graphic/77385.html" rel="external">figure 1</a>). In addition to commonly recognized hormonal and metabolic complications such as anemia and hyperparathyroidism, CKD complications include increased risks for systemic drug toxicity, cardiovascular disease, infection, cognitive impairment, and impaired physical function [<a href="#rid20">20-23</a>]. Complications are more likely to occur at later stages, and may lead to death before kidney disease progresses to kidney failure. Complications may also arise from the adverse effects of interventions used to prevent or treat the disease. (See  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Treatment of the complications of severe CKD'</a>.)</p><p class="headingAnchor" id="H27258481"><span class="h2">Definition of CKD</span><span class="headingEndMark"> — </span>We agree with the KDOQI and KDIGO guidelines that CKD is defined by the presence of kidney damage <strong>or</strong> decreased kidney function <strong>for three or more months</strong>, irrespective of the cause  (<a class="graphic graphic_table graphicRef80632" href="/d/graphic/80632.html" rel="external">table 1</a>) [<a href="#rid24">24</a>]. The persistence of the damage or decreased function for at least three months is <strong>necessary</strong> to distinguish CKD from acute kidney disease. Kidney damage refers to pathologic abnormalities, whether established via kidney biopsy or imaging studies, or inferred from markers such as urinary sediment abnormalities or increased rates of urinary albumin excretion. Decreased kidney function refers to a decreased glomerular filtration rate (GFR), which is usually estimated (eGFR) using serum creatinine and one of several available equations. (See  <a class="medical medical_review" href="/d/html/102837.html" rel="external">"Chronic kidney disease (newly identified): Clinical presentation and diagnostic approach in adults"</a>.)</p><p>A discussion of the limitations of GFR estimation, including problems associated with using the serum creatinine in patients who are not in steady-state (such as hospitalized patients) and those with diminished creatinine generation, is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p>An important aspect of the definition is that the criteria are objective and can be ascertained by means of simple laboratory tests. Identifying patients with CKD can therefore be done without identification of the underlying cause and without consultation with a nephrologist. However, many patients should, under the circumstances outlined below, be referred to a nephrologist or other specialist with expertise in evaluating and managing patients with CKD in order to identify the cause of the CKD and to provide recommendations for therapies to reverse the kidney disease, slow progression, or treat complications. (See <a class="local">'Referral to a specialist'</a> below and  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Referral to nephrologists'</a>.)</p><p class="headingAnchor" id="H27258566"><span class="h3">Kidney damage</span><span class="headingEndMark"> — </span>Kidney damage includes pathologic abnormalities in the native or transplanted kidney. Kidney damage is identified in most cases by the presence of one of the following clinical markers  (<a class="graphic graphic_table graphicRef80632" href="/d/graphic/80632.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Albuminuria − In clinical practice, albuminuria is the most frequently assessed marker of kidney damage. Albuminuria reflects increased glomerular permeability to macromolecules [<a href="#rid25">25</a>]. Albuminuria may reflect primary kidney disease or kidney involvement in systemic disease. In particular, albuminuria may represent widespread endothelial dysfunction, such as can be seen with hypertension, diabetes, hypercholesterolemia, smoking, obesity, and other disorders.</p><p></p><p class="bulletIndent1">Although a number of different measurement methods have been used to assess and define albuminuria  (<a class="graphic graphic_table graphicRef56286" href="/d/graphic/56286.html" rel="external">table 2</a>), the albumin-to-creatinine ratio (ACR) in an untimed "spot" urine has many advantages (<a class="calc calc_professional" href="/d/html/95019.html" rel="external">calculator 1</a>) [<a href="#rid26">26,27</a>]. The generally accepted threshold for an abnormally elevated ACR is 30 mg/g (3.4 mg/mmol) or greater. ACR can be estimated by converting spot urine protein-to-creatinine ratio and dipstick urine protein using various formulas [<a href="#rid28">28,29</a>]. (See  <a class="medical medical_review" href="/d/html/3110.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/3089.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults"</a> and  <a class="medical medical_review" href="/d/html/3084.html" rel="external">"Overview of heavy proteinuria and the nephrotic syndrome"</a>.)</p><p></p><p class="bulletIndent1">We agree with the KDIGO recommendation that albuminuria above this threshold, regardless of cause, should be considered part of the definition of CKD. Individuals with a urine ACR &gt;30 mg/g (or equivalent) have a significantly increased risk for all-cause and cardiovascular mortality, ESKD, AKI and CKD progression compared with those who have a lower ACR  (<a class="graphic graphic_figure graphicRef68921" href="/d/graphic/68921.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef58089" href="/d/graphic/58089.html" rel="external">figure 3</a>), even when eGFR is normal [<a href="#rid12">12,14-16,24</a>]. As an example, individuals with an ACR of 30 to 299 mg/g (3.4 to 34 mg/mmol) or equivalent and an eGFR of 90 to 105 mL/min per 1.73 m<sup>2</sup> had an 11-fold higher relative risk for ESKD than those whose eGFR was similar but whose ACR was below 30 mg/g.</p><p></p><p class="bulletIndent1">In the KDOQI and KDIGO definition, the threshold value for abnormally elevated urine ACR (30 mg/g or higher) is applied to adults of all ages, both men and women, and all racial-ethnic groups, despite potential differences in creatinine excretion rate among these groups. When this single threshold was applied to a population-based cohort in the United States, the prevalence of albuminuria was significantly greater in women compared with men [<a href="#rid30">30</a>]. Although urinary albumin concentrations were similar, women had lower urinary creatinine concentrations. Thus, sex-specific ACR thresholds that better predict a 24-hour urinary albumin excretion of 30 mg or higher (≥25 mg/g for women and ≥17 mg/g for men) have been used in some studies [<a href="#rid31">31</a>]. However, we agree with the KDIGO recommendation to use a common albuminuria threshold for all adults due to the ease of widespread implementation. Albumin excretion rate in a timed urine collection can be used for confirmation when clinical circumstances require more accurate measurement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary sediment abnormalities − Urinary sediment abnormalities such as red or white blood cell casts may indicate the presence of glomerular injury or tubular inflammation. (See  <a class="medical medical_review" href="/d/html/7196.html" rel="external">"Urinalysis in the diagnosis of kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging abnormalities − Kidney damage may be detected by the presence of imaging abnormalities such as polycystic kidneys, hydronephrosis, and small and echogenic kidneys. (See  <a class="medical medical_review" href="/d/html/7194.html" rel="external">"Radiologic assessment of kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pathologic abnormalities − A kidney biopsy may reveal evidence for glomerular, vascular, or tubulointerstitial disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kidney transplantation − Patients with a history of kidney transplantation are assumed to have kidney damage whether or not they have documented abnormalities on kidney biopsy or markers of kidney damage.</p><p></p><p class="headingAnchor" id="H27258759"><span class="h3">Decreased GFR</span><span class="headingEndMark"> — </span>Glomerular filtration rate (GFR) is generally considered to be the best index of overall kidney function, and declining GFR is the hallmark of progressive kidney disease [<a href="#rid32">32</a>]. Measured GFR varies in normal individuals by age and sex  (<a class="graphic graphic_figure graphicRef73824" href="/d/graphic/73824.html" rel="external">figure 4</a>) [<a href="#rid33">33</a>], dietary protein intake, and possibly by other factors. Based upon clearance measurements in healthy people and in people with kidney disease, the widely accepted threshold defining a decreased GFR is less than 60 mL/min per 1.73 m<sup>2</sup>; kidney failure is defined as a GFR &lt;15 mL/min per 1.73 m<sup>2</sup> or treatment by dialysis  (<a class="graphic graphic_table graphicRef80632" href="/d/graphic/80632.html" rel="external">table 1</a>).</p><p>We agree with KDIGO that a measured GFR below this threshold should be considered part of the definition of CKD. GFR can be measured directly using the clearance of exogenous filtration markers such as inulin, iothalamate, or <a class="drug drug_general" data-topicid="8927" href="/d/drug information/8927.html" rel="external">iohexol</a> [<a href="#rid34">34</a>]. However, these measurement methods are complex to implement. Thus, in clinical practice, GFR is typically <strong>estimated</strong> (estimated GFR, or eGFR) from the serum concentration of creatinine, an endogenous filtration marker. Since 2013, the eGFR is reported routinely by 90 percent of clinical laboratories in the United States whenever the serum creatinine is measured [<a href="#rid35">35</a>]. Serum creatinine is measured frequently, and eGFR reporting has led to increased detection of CKD [<a href="#rid36">36,37</a>].</p><p>In routine practice, therefore, individuals who have an eGFR below 60 mL/min per 1.73 m<sup>2</sup> are defined as having CKD. These individuals have a significantly increased risk for all-cause and cardiovascular mortality, ESKD, AKI and CKD progression in compared with those whose eGFR is 60 mL/min per 1.73 m<sup>2</sup> or higher  (<a class="graphic graphic_figure graphicRef68921" href="/d/graphic/68921.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef58089" href="/d/graphic/58089.html" rel="external">figure 3</a>), even if the ACR is normal [<a href="#rid12">12,14-16,24</a>]. As an example, individuals with an eGFR of 45 to 59 mL/min per 1.73 m<sup>2</sup> and a urine ACR less than 10 mg/g had a fivefold higher relative risk of ESKD compared than those with a similarly normal ACR but with an eGFR of 60 mL/min per 1.73 m<sup>2</sup> or greater.</p><p>However, as noted below, we do not generally recommend that patients who have an isolated decreased eGFR (eg, an eGFR of 45 to 59 mL/min per 1.73 m<sup>2</sup> without an elevation in albuminuria) be referred for care by a nephrologist or other specialist with expertise in caring for patients with kidney disease. (See <a class="local">'Referral to a specialist'</a> below.)</p><p class="headingAnchor" id="H26100367"><span class="h4">Similar thresholds for older adults</span><span class="headingEndMark"> — </span>Large meta-analyses have also found that the associations between eGFR and adverse events such as death and ESKD do <strong>not</strong> vary substantially with age [<a href="#rid12">12,38</a>]. In a meta-analysis that included approximately 1.5 million individuals from multiple cohorts, for example, the associations between lower levels of eGFR with the incidence of death, cardiovascular disease, ESKD, and progression of kidney disease were similar among those older and younger than 65 years [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>All-cause mortality – Compared with individuals who had an eGFR between 90 and 105 mL/min per 1.73 m<sup>2</sup> and an ACR less than 10 mg/g, the relative risks for all-cause mortality among those who had an eGFR between 45 and 59 mL/min per 1.73 m<sup>2</sup> and an ACR less than 10 mg/g (ie, those with an "isolated" reduction in eGFR) were 1.9 (95% CI, 1.4-2.5) in those younger than 65 years and 1.2 (95% CI, 1.0-1.5) in those older than 65 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular mortality – Compared with individuals who had an eGFR between 90 and 105 mL/min per 1.73 m<sup>2</sup> and an ACR less than 10 mg/g, the relative risks for cardiovascular mortality among those who had an eGFR between 45 and 59 mL/min per 1.73 m<sup>2</sup> and an ACR less than 10 mg/g (ie, those with an "isolated" reduction in eGFR) were 1.3 (95% CI, 0.6-3.2) in those younger than 65 years and 1.4 (95% CI, 1.2-1.8) in those older than 65 years. In addition, absolute rates of cardiovascular mortality were higher in those older than 65 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>End-stage kidney disease – Compared with individuals who had an eGFR of 60 mL/min per 1.73 m<sup>2</sup> or more, the relative risks for ESKD among those who had an eGFR between 45 and 59 mL/min per 1.73 m<sup>2</sup> were 3.1 (95% CI, 1.1-8.3) in those younger than 65 years and 3.4 (95% CI, 1.6-7.2) in those older than 65 years. In contrast to cardiovascular mortality, absolute rates of ESKD were lower in those older than 65 years.</p><p></p><p>Thus, for older adults, the relative risk for all-cause mortality associated with a reduction in eGFR is somewhat smaller than it is in younger individuals, but the relative risks are similar for cardiovascular mortality and ESKD in both younger and older individuals. A more detailed meta-analysis confirmed that the relative risks for all-cause mortality associated with a given eGFR were smaller among older individuals; however, the absolute risks associated with a given eGFR were higher among older individuals due to the elevated baseline risk for mortality [<a href="#rid38">38</a>].</p><p>There are limited data evaluating the association of isolated reductions in GFR with death and ESKD in older individuals (ie, age 75 years and older). However, reductions in GFR are associated with other CKD complications in such patients. In a study of 2272 individuals 80 years of age and older from the general population, the prevalences anemia and hyperparathyroidism were both significantly higher in those whose eGFR was between 45 and 59 mL/min per 1.73 m<sup>2</sup> compared with those whose eGFR was greater than or equal to 60 mL/min per 1.73 m<sup>2</sup> [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H365882892"><span class="h4">Similar thresholds in low-risk groups</span><span class="headingEndMark"> — </span>Large meta-analyses have also compared risks for all-cause mortality, cardiovascular mortality, and ESKD by eGFR and albuminuria across different risk groups. In general, the relative risks for adverse outcomes associated with lower eGFR or higher albuminuria were as high (or higher) among the low-risk groups [<a href="#rid40">40-43</a>]. These data support similar thresholds for defining CKD irrespective of sex, race, comorbid hypertension, or diabetes.</p><p class="headingAnchor" id="H1053952"><span class="h4">GFR estimation</span><span class="headingEndMark"> — </span>The various glomerular filtration rate (GFR) estimating equations use serum creatinine along with some combination of factors such as age and sex as surrogates for the non-GFR determinants of serum creatinine, and provide more accurate estimates of measured GFR than serum creatinine alone [<a href="#rid34">34,44,45</a>]. Commonly used estimating equations are imperfect, providing GFR estimates that can occasionally be widely disparate from, the measured GFR. A detailed discussion of the limitations of GFR estimation is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p>The Modification of Diet in Renal Disease (MDRD) Study equation and the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation were commonly used GFR estimating equations [<a href="#rid46">46-50</a>]. Both equations use age, sex, and race in addition to serum creatinine. Modifications of the equations for other geographical regions and racial-ethnic groups have been performed [<a href="#rid51">51,52</a>]. Use of these equations is <strong>not</strong> recommended.</p><p>Subsequently, the 2021 CKD-EPI creatinine equation was developed from the same data as the 2009 equation, but without a coefficient for race, and this is now the recommended equation for estimating GFR (<a class="calc calc_professional" href="/d/html/15635.html" rel="external">calculator 2</a>) [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p>Cystatin C is an alternative endogenous filtration marker that may have advantages over creatinine for GFR estimation because its non-GFR determinants are less affected by muscle mass and because it is more predictive of subsequent cardiovascular disease and mortality [<a href="#rid54">54-57</a>]. Use of cystatin C and creatinine together enables more accurate GFR estimates [<a href="#rid55">55,58</a>], and more accurate predictions of risk [<a href="#rid54">54,59,60</a>], although we are not recommending this strategy at this time. (See  <a class="medical medical_review" href="/d/html/2359.html" rel="external">"Assessment of kidney function"</a> and  <a class="medical medical_review" href="/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease", section on 'Cystatin C and other markers of kidney function'</a>.)</p><p>Like all diagnostic tests, interpretation of the eGFR should be influenced by the prior probability of disease. An isolated decreased eGFR in an otherwise healthy individual is more likely to be a false positive than in individuals with other markers of kidney damage or who have known risk factors for kidney disease. Confirmation of decreased eGFR by measurement of GFR using an exogenous filtration marker, measurement of creatinine clearance, or estimation of GFR using serum cystatin C is warranted when decisions depend upon more accurate knowledge of GFR, such as determining eligibility for kidney donation or adjusting the dose of toxic drugs that are excreted by the kidneys [<a href="#rid44">44</a>]. In most cases, however, eGFR using serum creatinine is appropriate for diagnosis, staging, and management of CKD.</p><p class="headingAnchor" id="H22697785"><span class="h3">Confirming the chronicity of damage or decreased function</span><span class="headingEndMark"> — </span>As noted above, the KDIGO guidelines require that the damage or decreased function be persistent for at least three months in order to make a diagnosis of CKD. Chronicity may be documented or inferred. When evidence of kidney damage or decreased function is first apparent, confirmation of chronicity can be obtained by one of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Review of past measurements or estimates of GFR</p><p class="bulletIndent1"><span class="glyph">●</span>Review of past measurements of albuminuria or proteinuria</p><p class="bulletIndent1"><span class="glyph">●</span>Review of past urine dipstick and sediment examinations</p><p class="bulletIndent1"><span class="glyph">●</span>Imaging findings, such as reduced kidney volume and reduction in cortical thickness, or presence of multiple cysts</p><p class="bulletIndent1"><span class="glyph">●</span>Obtaining repeat measurements within and beyond the three-month point</p><p></p><p>In clinical practice, it is usually not difficult to evaluate chronicity. For patients without evidence of chronicity, repeat testing is <strong>essential</strong> to rule out acute kidney disease. In addition, repeat testing is necessary in patients who have an eGFR or ACR near the threshold values for the CKD definition (ie, an eGFR just below 60 mL/min per 1.73 m<sup>2</sup> or an ACR just above 30 mg/g [3.4 mg/mmol]). In patients with these borderline values, both biological and analytical variations in serum creatinine and urinary albumin may result in the diagnosis of CKD not being confirmed [<a href="#rid27">27,61</a>].</p><p>Several studies have demonstrated the importance of repeat testing when evidence for chronicity is not already available at the time damage or decreased function is first recognized [<a href="#rid62">62-65</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of approximately 14,000 individuals from the general population with an eGFR greater than or equal to 60 mL/min per 1.73 m<sup>2</sup> who had repeated ACR measurements after a two-week interval, persistence of an ACR between 30 and 300 mg/g (3.4 to 34 mg/mmol) and an ACR greater than 300 mg/g at two weeks was 54 and 73 percent, respectively [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another general population cohort of 18,066 individuals with repeat measurements of serum creatinine separated by a mean of three years, 1169 (6.5 percent) had an eGFR less than 60 mL/min per 1.73 m<sup>2</sup> at baseline [<a href="#rid65">65</a>]. At three years, 891 of these individuals (76 percent) still had a reduced eGFR. The risk of subsequent adverse cardiovascular events was higher in those with persistently low eGFR than in those whose eGFR rose to above 60 mL/min per 1.73 m<sup>2</sup> at three years.</p><p></p><p class="headingAnchor" id="H27258970"><span class="h2">Staging of CKD</span><span class="headingEndMark"> — </span>The purpose of CKD staging is to guide management, including stratification of risk for progression and complications of CKD. Risk stratification is used as a guide to inform appropriate treatments and the intensity of monitoring and patient education [<a href="#rid1">1,4</a>]. In patients who are diagnosed with CKD using the criteria described above, staging of the CKD is done according to  (<a class="graphic graphic_table graphicRef70597" href="/d/graphic/70597.html" rel="external">table 3</a>) [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cause of disease</p><p class="bulletIndent1"><span class="glyph">●</span>Six categories of GFR (G stages)</p><p class="bulletIndent1"><span class="glyph">●</span>Three categories of albuminuria (A stages) </p><p></p><p>Staging patients with CKD according to cause, GFR, and albuminuria enhances risk stratification for the major complications of CKD  (<a class="graphic graphic_figure graphicRef68921" href="/d/graphic/68921.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef58089" href="/d/graphic/58089.html" rel="external">figure 3</a> and <a class="graphic graphic_table graphicRef55646" href="/d/graphic/55646.html" rel="external">table 4</a>). Low GFR is a stronger predictor of CKD complications than high albuminuria [<a href="#rid66">66</a>]. An overview of the management of patients with according to stage of CKD is provided elsewhere. (See  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H27259103"><span class="h3">Cause of disease</span><span class="headingEndMark"> — </span>Identifying the cause of kidney disease (eg, diabetes, drug toxicity, auto-immune diseases, urinary tract obstruction, kidney transplantation, etc.) enables specific therapy directed at preventing further injury. In addition, the cause of kidney disease has implications for the rate of progression and the risk of complications  (<a class="graphic graphic_table graphicRef55646" href="/d/graphic/55646.html" rel="external">table 4</a>).</p><p>It can be difficult to ascertain the cause of kidney disease. In clinical practice, CKD is most often discovered as decreased eGFR during the evaluation and management of other medical conditions. The evaluation of patients diagnosed with CKD is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7188.html" rel="external">"Diagnostic approach to adult patients with subacute kidney injury in an outpatient setting"</a>.)</p><p class="headingAnchor" id="H27259120"><span class="h3">GFR</span><span class="headingEndMark"> — </span>The glomerular filtration rate (GFR; G-stages) follow the original CKD classification scheme  (<a class="graphic graphic_table graphicRef70597" href="/d/graphic/70597.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>G1 − GFR &gt;90 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G2 − GFR 60 to 89 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G3a − GFR 45 to 59 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G3b − GFR 30 to 44 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G4 − GFR 15 to 29 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G5 − GFR &lt;15 mL/min per 1.73 m<sup>2</sup> or treatment by dialysis</p><p></p><p>Since the original KDOQI classification was published, stage 3 CKD (a GFR of 30 to 59 mL/min per 1.73 m<sup>2</sup>) has been subdivided into GFR stages 3a and 3b to more accurately reflect the continuous association between lower GFR and risk for mortality and adverse kidney outcomes  (<a class="graphic graphic_figure graphicRef68921" href="/d/graphic/68921.html" rel="external">figure 2</a>). Patients receiving treatment with dialysis are subclassified as GFR stage 5D to highlight the specialized care that they require.</p><p class="headingAnchor" id="H27259169"><span class="h3">Albuminuria</span><span class="headingEndMark"> — </span>The three albuminuria stages follow familiar definitions of normal, moderately increased (formerly called "microalbuminuria"), and severely increased (formerly called "macroalbuminuria" and nephrotic range) albuminuria  (<a class="graphic graphic_table graphicRef70597" href="/d/graphic/70597.html" rel="external">table 3</a>) (<a class="calc calc_professional" href="/d/html/95019.html" rel="external">calculator 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>A1 − ACR &lt;30 mg/g (&lt;3.4 mg/mmol)</p><p class="bulletIndent1"><span class="glyph">●</span>A2 − ACR 30 to 299 mg/g (3.4 to 34.0 mg/mmol)</p><p class="bulletIndent1"><span class="glyph">●</span>A3 − ACR ≥300 mg/g (&gt;34.0 mg/mmol)</p><p></p><p>The addition of albuminuria staging to GFR staging is new since the original KDOQI classification scheme was published [<a href="#rid1">1-3</a>]. Albuminuria staging has been added because of the graded increase in risk for mortality, progression of CKD, and ESKD at higher levels of albuminuria, independent of eGFR, without an apparent threshold value  (<a class="graphic graphic_figure graphicRef68921" href="/d/graphic/68921.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef58089" href="/d/graphic/58089.html" rel="external">figure 3</a>) [<a href="#rid12">12,24</a>]. The increase in risk is significant for urine ACR values ≥30 mg/g, even when GFR is &gt;60 mL/min per 1.73 m<sup>2</sup>, consistent with the current threshold value for albuminuria (≥30 mg/g) as a marker of kidney damage. An increased risk is also apparent with urine ACR levels between 10 and 29 mg/g ("high normal" albuminuria), suggesting that levels below 30 mg/g may also warrant increased attention.</p><p class="headingAnchor" id="H1054193"><span class="h3">Purpose for and implications of CKD staging</span><span class="headingEndMark"> — </span>The staging system for CKD is intended to aid clinicians in the management of patients with CKD by identifying those with the most severe disease who are, therefore, at greatest risk for progression and complications. Staging according to cause, GFR, and albuminuria allows for a more complete description of risk for the major adverse outcomes of CKD.</p><p>CKD staging is <strong>not</strong> meant to imply that there are GFR or albuminuria thresholds in CKD severity, or that all patients in the same GFR and albuminuria category will have the same prognosis. As an example, a patient with a GFR of 15 mL/min per 1.73 m<sup>2</sup> likely has more severe kidney disease, and may be at higher risk for complications, than someone with a GFR of 29 mL/min per 1.73 m<sup>2</sup>, even though both patients have GFR stage G4.</p><p>Patients with already diagnosed CKD can now be staged according to the cause of kidney disease and then into 18 separate categories with differing degrees of risk for progression to all-cause mortality, cardiovascular mortality, ESKD, CKD progression, and acute kidney injury. The relative risk for each outcome is higher with more severe GFR and ACR stages. Based upon these findings, a "heat map" can be constructed that divides patients with CKD into the following three broad risk categories based upon the likelihood of developing future kidney and cardiovascular complications (eg, ESKD, cardiovascular death)  (<a class="graphic graphic_figure graphicRef59716" href="/d/graphic/59716.html" rel="external">figure 5</a>); the proportion of the population in the United States with CKD (ascertained by eGFR and albuminuria) that falls into these risk categories is also given [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate risk (yellow) – 73 percent of patients with CKD</p><p class="bulletIndent1"><span class="glyph">●</span>High risk (orange) – 18 percent of patients with CKD</p><p class="bulletIndent1"><span class="glyph">●</span>Very high risk (red) – 9 percent of patients with CKD</p><p></p><p>These three broad risk categories may help clinicians decide whether or not to refer their patients to a nephrologist or specialist with expertise in caring for patients with CKD, and to develop a clinical action plan. A similar definition of risk categories was proposed based upon analysis of a large cohort in Canada [<a href="#rid67">67</a>]. (See <a class="local">'Referral to a specialist'</a> below and <a class="local">'Clinical action plan'</a> below.)</p><p>However, the heat map must be considered in the appropriate context:</p><p class="bulletIndent1"><span class="glyph">●</span>First, it is derived from a meta-analysis in which approximately 1.5 million individuals were followed for a mean of five years. If a patient with CKD is staged initially as low risk, this does <strong>not</strong> mean the he or she will remain low risk and not progress over the next several decades. As an example, a patient with autosomal dominant polycystic kidney disease (ADPKD) who is diagnosed by imaging at a young age and who has a normal eGFR and no proteinuria may be low risk for developing ESKD in the short term, but has a high long-term risk of progressive CKD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Second, the heat map applies to patients who have been diagnosed with CKD. Individuals who fall into the low risk (green) categories have CKD based upon markers of kidney damage other than albuminuria. Such individuals are generally not identified in population surveys.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Third, the risk graduation displayed in the heat map is meant to compare patients with the same cause of CKD.</p><p></p><p>Additional details describing the association between CKD and risk for cardiovascular disease are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease"</a>.)</p><p class="headingAnchor" id="H923134"><span class="h1">IMPLICATIONS FOR CLINICAL PRACTICE AND PUBLIC HEALTH</span><span class="headingEndMark"> — </span>The definition and classification of CKD has several important implications for public health and clinical practice.</p><p class="headingAnchor" id="H923152"><span class="h2">Prevalence of CKD</span><span class="headingEndMark"> — </span>Because patients with CKD have a high rate of end-stage kidney disease (ESKD), cardiovascular disease, and death, CKD is an appropriate target for prevention, early detection, and management by non-nephrologist clinicians and public health agencies [<a href="#rid68">68,69</a>]. Using the current definitions, the prevalence of CKD in the United States during the interval from 1999 to 2006 was 11.5 percent (42 percent in glomerular filtration rate [GFR] stages 1-2 and 58 percent in GFR stages 3-4), equivalent to approximately 23 million adults [<a href="#rid48">48</a>]. This was similar to the prevalence of other chronic noncommunicable diseases in the United States at that time, such as diabetes (10.6 percent, 23.4 million) [<a href="#rid68">68</a>]. The age-standardized global prevalence of CKD in 2010 was estimated as 10.4 percent in men and 11.8 percent in women, although there was heterogeneity across regions [<a href="#rid70">70</a>].</p><p>In 2013, reduced GFR was associated with 4 percent of deaths worldwide or 2.2 million deaths. More than one-half of these attributable deaths were cardiovascular deaths (1.2 million), whereas 0.96 million were ESKD-related deaths. Compared with other risk factors, reduced GFR ranked below hypertension, overweight-obesity, and high plasma glucose, but similarly with high cholesterol, as a risk factor for disability-adjusted life years in both developed and developing world regions [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H923181"><span class="h2">Application to older adults</span><span class="headingEndMark"> — </span>The prevalence of CKD in people 70 years and older in the United States is high (approximately 45 percent) [<a href="#rid48">48,72</a>]. It is possible that the association between advancing age and lower eGFR and higher albuminuria may be due to vascular disease rather than a natural aging process [<a href="#rid72">72-74</a>]. The fact that lower eGFR values are associated with increased kidney and cardiovascular disease rates in older as well as younger individuals is not consistent with the interpretation that decreased eGFR with aging is "normal" or "physiological." Rather, it suggests that decreased eGFR in older adults is evidence of disease. Similarly, the increased risk for adverse kidney outcomes for individuals whose urine albumin-to-creatinine ratio (ACR) is between 30 and 299 mg/g (3.4 to 34 mg/mmol) in older as well as younger adults is not consistent with the interpretation that moderately increased albuminuria (formerly called "microalbuminuria") is only a marker for increased cardiovascular disease risk.</p><p>As in diabetes, hypertension, or hypercholesterolemia, selecting a threshold value to define the disease must balance the risk of "labeling" low-risk individuals against the benefit of early detection of high-risk individuals [<a href="#rid75">75-78</a>]. As an example, the systolic blood pressure threshold for the definition of hypertension, previously higher in older adults than in the young, is now the same for all ages. We agree with the position of KDIGO that definition of CKD should be the same for all ages, although the evaluation and management should be adapted for age [<a href="#rid79">79,80</a>].</p><p class="headingAnchor" id="H923198"><span class="h2">CKD classification to assign prognosis for individuals</span><span class="headingEndMark"> — </span>The staging system will help clinicians to determine how and how intensely to treat and monitor patients with established CKD. More accurate risk prediction for an individual patient can be accomplished by the use of risk-prediction instruments [<a href="#rid81">81</a>]. In addition to eGFR and albuminuria, the cause of kidney disease, as well as other factors (eg, age, cholesterol levels, smoking status, and others), should be considered in estimating prognosis. As examples, one instrument for predicting risk of progression of CKD from eGFR &lt;60 mL/min per 1.73 m<sup>2</sup> to ESKD that used age, sex, eGFR, and albuminuria was developed from a large cohort of patients referred to nephrologists and has been extensively validated [<a href="#rid82">82,83</a>]. Another instrument for predicting risks for development of ESKD, cardiovascular disease, and mortality in patients with eGFR &lt;30 mL/min per 1.73 m<sup>2</sup> used additional variables and has also undergone extensive validation [<a href="#rid84">84</a>]. We think such models could eventually be useful tools to help guide decision-making for individual patients.</p><p class="headingAnchor" id="H923217"><span class="h1">REFERRAL TO A SPECIALIST</span><span class="headingEndMark"> — </span>Referral depends upon practice patterns, which are not uniform across healthcare systems or geographic regions, even within countries. As a result, there are numerous recommendations that propose indications for referral to nephrologists, and none have been universally adopted [<a href="#rid85">85-89</a>]. However, one indication that is common to most guidelines is that all patients with severely decreased glomerular filtration rate (GFR; estimated GFR [eGFR] less than 30 mL/min per 1.73 m<sup>2</sup>, GFR stage 4) should be referred for co-management with a nephrologist. Patients at or below this level of eGFR have already demonstrated that they have progressive kidney disease, and therefore are at high risk for progression to end-stage kidney disease (ESKD). In such patients, late referral to a nephrologist (ie, less than three months before the start of dialysis therapy) is associated with higher mortality after the initiation of dialysis [<a href="#rid90">90,91</a>].</p><p>Patients with severely decreased eGFR require preparation for the possible onset of ESKD. Preparation involves a discussion regarding kidney replacement therapy (dialysis and transplantation), and conservative therapy for those not willing or unable to undergo kidney replacement therapy. In patients electing replacement therapy, timely creation of vascular access for hemodialysis, home dialysis training, and donor evaluation for preemptive transplantation should occur. Several studies have demonstrated that patients who are referred to nephrology late are less likely to initiate dialysis with a functioning fistula [<a href="#rid87">87,92,93</a>].</p><p>There is less consensus about referral for patients with higher eGFR. Based in part upon current guidelines [<a href="#rid24">24,86,87</a>], we recommend that, in addition to referral of all patients who have an eGFR less than 30 mL/min per 1.73 m<sup>2</sup>, patients with CKD who meet one or more of the following criteria be referred to a nephrologist or other clinician skilled in managing patients with CKD:</p><p class="bulletIndent1"><span class="glyph">●</span>Urine albumin-to-creatinine ratio (ACR) ≥300 mg/g (34 mg/mmol), including nephrotic syndrome</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematuria not secondary to urological conditions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inability to identify a presumed cause of CKD</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>eGFR decline of more than 30 percent in fewer than four months without an obvious explanation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Difficult to manage complications such as anemia requiring erythropoietin therapy, and abnormalities of bone and mineral metabolism requiring phosphorus binders or vitamin D preparations</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum potassium greater than 5.5 mEq/L</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Difficult to manage drug complications</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients under the age of 18 years</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resistant hypertension</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent or extensive nephrolithiasis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Confirmed or presumed hereditary kidney disease, such as polycystic kidney disease, Alport syndrome, or autosomal dominant interstitial kidney disease:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/1677.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Treatment"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/6093.html" rel="external">"Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/1685.html" rel="external">"Autosomal dominant tubulointerstitial kidney disease"</a>.)</p><p></p><p class="bulletIndent1">Nephrologists can assist primary care clinicians and other specialists in the diagnosis and care of patients at all stages of CKD. These functions include determination of the cause of CKD, recommendations for specific therapy, suggestions for treatments to slow progression in patients who have not responded to conventional therapies, identification and treatment for kidney disease-related complications, and preparation for dialysis. Because patients with CKD are at risk for a diverse set of adverse outcomes (not just kidney failure), referral to other appropriate specialists (eg, cardiologists for those with complex cardiovascular disease) should also be considered.</p><p></p><p class="headingAnchor" id="H923312"><span class="h1">CLINICAL ACTION PLAN</span><span class="headingEndMark"> — </span>Suggestions for the treatment and monitoring of patients who are diagnosed with CKD vary according to the stage of CKD based upon cause, glomerular filtration rate (GFR), and albuminuria. A discussion of the recommended clinical action plan according to CKD stage is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H4110282357"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H6845174"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Manifestations</strong> – Chronic kidney disease (CKD) is a heterogeneous group of disorders characterized by alterations in kidney structure and function, which manifest in various ways depending upon the underlying cause or causes and the severity of disease  (<a class="graphic graphic_figure graphicRef77385" href="/d/graphic/77385.html" rel="external">figure 1</a>). The term "end-stage kidney disease" (ESKD) generally refers to CKD treated with either dialysis or transplantation. (See <a class="local">'Framework and conceptual model'</a> above.)</p><p></p><p class="bulletIndent1">CKD is usually asymptomatic in its early stages. Symptoms appear in later stages in association with complications  (<a class="graphic graphic_figure graphicRef77385" href="/d/graphic/77385.html" rel="external">figure 1</a>). In addition to commonly recognized hormonal and metabolic complications such as anemia and hyperparathyroidism, CKD complications include increased risks for systemic drug toxicity, cardiovascular disease, infection, cognitive impairment, and impaired physical function. (See <a class="local">'Framework and conceptual model'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of CKD</strong> – CKD is defined by the presence of kidney damage <strong>or</strong> decreased kidney function <strong>for three or more months</strong>, irrespective of the cause  (<a class="graphic graphic_table graphicRef80632" href="/d/graphic/80632.html" rel="external">table 1</a>). The persistence of the damage or decreased function for at least three months is <strong>necessary</strong> to distinguish CKD from acute kidney disease. Kidney damage refers to pathologic abnormalities, whether established via kidney biopsy or imaging studies or inferred from markers such as urinary sediment abnormalities or increased rates of urinary albumin excretion. Decreased kidney function refers to a decreased glomerular filtration rate (GFR), which is usually estimated (eGFR) using serum creatinine and one of several available equations. (See <a class="local">'Definition of CKD'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney damage is identified in most cases by the presence of albuminuria, urinary sediment abnormalities, anatomic abnormalities discovered with imaging studies, pathologic abnormalities discovered with kidney biopsy, or a history of kidney transplantation  (<a class="graphic graphic_table graphicRef80632" href="/d/graphic/80632.html" rel="external">table 1</a>). (See <a class="local">'Kidney damage'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased kidney function is identified in most cases by an eGFR less than 60 mL/min per 1.73 m<sup>2</sup>  (<a class="graphic graphic_table graphicRef80632" href="/d/graphic/80632.html" rel="external">table 1</a>). Estimation of GFR is discussed in more detail elsewhere. (See <a class="local">'Decreased GFR'</a> above and  <a class="medical medical_review" href="/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p></p><p class="bulletIndent1">Confirmation of chronicity can be obtained by one of the following (see <a class="local">'Confirming the chronicity of damage or decreased function'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Review of past measurements or estimates of GFR</p><p class="bulletIndent2"><span class="glyph">•</span>Review of past measurements of albuminuria or proteinuria</p><p class="bulletIndent2"><span class="glyph">•</span>Review of past urine dipstick and sediment examinations</p><p class="bulletIndent2"><span class="glyph">•</span>Imaging findings, such as reduced kidney volume and reduction in cortical thickness, or presence of multiple cysts</p><p class="bulletIndent2"><span class="glyph">•</span>Obtaining repeat measurements within and beyond the three-month point</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging of CKD</strong> – The purpose of CKD staging is to guide management, including stratification of risk for progression and complications of CKD  (<a class="graphic graphic_figure graphicRef68921" href="/d/graphic/68921.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef58089" href="/d/graphic/58089.html" rel="external">figure 3</a> and <a class="graphic graphic_table graphicRef55646" href="/d/graphic/55646.html" rel="external">table 4</a>). Risk stratification is used as a guide to inform appropriate treatments and the intensity of monitoring and patient education. In patients who are diagnosed with CKD using the criteria described above, staging of the CKD is done according to  (<a class="graphic graphic_table graphicRef70597" href="/d/graphic/70597.html" rel="external">table 3</a>) (see <a class="local">'Staging of CKD'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cause of disease – Identifying the cause of kidney disease (eg, diabetes, drug toxicity, auto-immune diseases, urinary tract obstruction, kidney transplantation, etc.) enables specific therapy directed at preventing further injury and has implications for the rate of progression and the risk of complications  (<a class="graphic graphic_table graphicRef55646" href="/d/graphic/55646.html" rel="external">table 4</a>). (See <a class="local">'Cause of disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Six categories of GFR (G stages) – The GFR (G-stages) are shown in the table  (<a class="graphic graphic_table graphicRef70597" href="/d/graphic/70597.html" rel="external">table 3</a>). Since the original Kidney Disease Outcomes Quality Initiative (KDOQI) classification was published, stage 3 CKD (a GFR of 30 to 59 mL/min per 1.73 m<sup>2</sup>) has been subdivided into GFR stages 3a and 3b to more accurately reflect the continuous association between lower GFR and risk for mortality and adverse kidney outcomes. (See <a class="local">'GFR'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Three categories of albuminuria (A stages) – The three albuminuria stages follow familiar definitions of normal, moderately increased (formerly called "microalbuminuria"), and severely increased (formerly called "macroalbuminuria" and nephrotic range) albuminuria  (<a class="graphic graphic_table graphicRef70597" href="/d/graphic/70597.html" rel="external">table 3</a>) (<a class="calc calc_professional" href="/d/html/95019.html" rel="external">calculator 1</a>). Albuminuria staging has been added because of the graded increase in risk for mortality, progression of CKD, and ESKD at higher levels of albuminuria, independent of eGFR. (See <a class="local">'Albuminuria'</a> above.)</p><p></p><p class="bulletIndent1">Based upon this staging, a "heat map" can be constructed that divides patients with CKD into three broad risk categories (moderate, high, and very high) based upon the likelihood of developing future kidney and cardiovascular complications (eg, ESKD, cardiovascular death)  (<a class="graphic graphic_figure graphicRef59716" href="/d/graphic/59716.html" rel="external">figure 5</a>). (See <a class="local">'Purpose for and implications of CKD staging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to refer</strong> – We recommend that, in addition to referral of all patients who have an eGFR less than 30 mL/min per 1.73 m<sup>2</sup>, patients with CKD who meet one or more of the following criteria be referred to a nephrologist or other clinician skilled in managing patients with CKD (see <a class="local">'Referral to a specialist'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urine albumin-to-creatinine ratio (ACR) ≥300 mg/g (34 mg/mmol), including nephrotic syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Hematuria not secondary to urological conditions</p><p class="bulletIndent2"><span class="glyph">•</span>Inability to identify a presumed cause of CKD</p><p class="bulletIndent2"><span class="glyph">•</span>eGFR decline of more than 30 percent in fewer than four months without an obvious explanation</p><p class="bulletIndent2"><span class="glyph">•</span>Difficult to manage complications such as anemia requiring erythropoietin therapy, and abnormalities of bone and mineral metabolism requiring phosphorus binders or vitamin D preparations</p><p class="bulletIndent2"><span class="glyph">•</span>Serum potassium greater than 5.5 mEq/L</p><p class="bulletIndent2"><span class="glyph">•</span>Difficult to manage drug complications</p><p class="bulletIndent2"><span class="glyph">•</span>Patients under the age of 18 years</p><p class="bulletIndent2"><span class="glyph">•</span>Resistant hypertension</p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent or extensive nephrolithiasis</p><p class="bulletIndent2"><span class="glyph">•</span>Confirmed or presumed hereditary kidney disease</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.</a></li><li><a class="nounderline abstract_t">Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137.</a></li><li><a class="nounderline abstract_t">Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67:2089.</a></li><li><a class="nounderline abstract_t">Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis 2009; 53:S4.</a></li><li><a class="nounderline abstract_t">Rettig RA, Norris K, Nissenson AR. Chronic kidney disease in the United States: a public policy imperative. Clin J Am Soc Nephrol 2008; 3:1902.</a></li><li><a class="nounderline abstract_t">Bauer C, Melamed ML, Hostetter TH. Staging of chronic kidney disease: time for a course correction. J Am Soc Nephrol 2008; 19:844.</a></li><li><a class="nounderline abstract_t">Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep 2010; 12:364.</a></li><li><a class="nounderline abstract_t">Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379:165.</a></li><li><a class="nounderline abstract_t">James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010; 375:1296.</a></li><li><a class="nounderline abstract_t">Winearls CG, Glassock RJ. Dissecting and refining the staging of chronic kidney disease. Kidney Int 2009; 75:1009.</a></li><li><a class="nounderline abstract_t">Eckardt KU, Berns JS, Rocco MV, Kasiske BL. Definition and classification of CKD: the debate should be about patient prognosis--a position statement from KDOQI and KDIGO. Am J Kidney Dis 2009; 53:915.</a></li><li><a class="nounderline abstract_t">Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80:17.</a></li><li><a class="nounderline abstract_t">Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79:1331.</a></li><li><a class="nounderline abstract_t">van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79:1341.</a></li><li><a class="nounderline abstract_t">Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80:93.</a></li><li><a class="nounderline abstract_t">Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073.</a></li><li><a class="nounderline abstract_t">KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:136.</a></li><li><a class="nounderline abstract_t">Hsu CY, Ordoñez JD, Chertow GM, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 2008; 74:101.</a></li><li><a class="nounderline abstract_t">James MT, Hemmelgarn BR, Wiebe N, et al. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet 2010; 376:2096.</a></li><li><a class="nounderline abstract_t">Fink JC, Brown J, Hsu VD, et al. CKD as an underrecognized threat to patient safety. Am J Kidney Dis 2009; 53:681.</a></li><li><a class="nounderline abstract_t">James MT, Quan H, Tonelli M, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 2009; 54:24.</a></li><li><a class="nounderline abstract_t">Hailpern SM, Melamed ML, Cohen HW, Hostetter TH. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2007; 18:2205.</a></li><li><a class="nounderline abstract_t">Wilhelm-Leen ER, Hall YN, K Tamura M, Chertow GM. Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey. Am J Med 2009; 122:664.</a></li><li><a class="nounderline abstract_t">Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011) 2013; 3:19.</a></li><li><a class="nounderline abstract_t">Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116:288.</a></li><li><a class="nounderline abstract_t">Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42:617.</a></li><li><a class="nounderline abstract_t">Miller WG, Bruns DE, Hortin GL, et al. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009; 55:24.</a></li><li><a class="nounderline abstract_t">Weaver RG, James MT, Ravani P, et al. Estimating Urine Albumin-to-Creatinine Ratio from Protein-to-Creatinine Ratio: Development of Equations using Same-Day Measurements. J Am Soc Nephrol 2020; 31:591.</a></li><li><a class="nounderline abstract_t">Sumida K, Nadkarni GN, Grams ME, et al. Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis : An Individual Participant-Based Meta-analysis. Ann Intern Med 2020; 173:426.</a></li><li><a class="nounderline abstract_t">Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 2002; 13:1034.</a></li><li><a class="nounderline abstract_t">Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996; 7:930.</a></li><li><a class="nounderline abstract_t">Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241:F85.</a></li><li class="breakAll">Wesson L. Physiology of the Human Kidney, Grune &amp; Stratton, New York 1969. p.96.</li><li><a class="nounderline abstract_t">Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473.</a></li><li><a class="nounderline abstract_t">Miller WG, Jones GRD. Estimated Glomerular Filtration Rate; Laboratory Implementation and Current Global Status. Adv Chronic Kidney Dis 2018; 25:7.</a></li><li><a class="nounderline abstract_t">Jain AK, McLeod I, Huo C, et al. When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. Kidney Int 2009; 76:318.</a></li><li><a class="nounderline abstract_t">Hemmelgarn BR, Zhang J, Manns BJ, et al. Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA 2010; 303:1151.</a></li><li><a class="nounderline abstract_t">Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012; 308:2349.</a></li><li><a class="nounderline abstract_t">Bowling CB, Inker LA, Gutiérrez OM, et al. Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications. Clin J Am Soc Nephrol 2011; 6:2822.</a></li><li><a class="nounderline abstract_t">Nitsch D, Grams M, Sang Y, et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 2013; 346:f324.</a></li><li><a class="nounderline abstract_t">Wen CP, Matsushita K, Coresh J, et al. Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. Kidney Int 2014; 86:819.</a></li><li><a class="nounderline abstract_t">Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380:1649.</a></li><li><a class="nounderline abstract_t">Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380:1662.</a></li><li><a class="nounderline abstract_t">Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009; 20:2305.</a></li><li><a class="nounderline abstract_t">Levey AS, Titan SM, Powe NR, et al. Kidney Disease, Race, and GFR Estimation. Clin J Am Soc Nephrol 2020; 15:1203.</a></li><li><a class="nounderline abstract_t">Stevens LA, Coresh J, Feldman HI, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 2007; 18:2749.</a></li><li><a class="nounderline abstract_t">Earley A, Miskulin D, Lamb EJ, et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012; 156:785.</a></li><li><a class="nounderline abstract_t">Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604.</a></li><li><a class="nounderline abstract_t">Stevens LA, Schmid CH, Greene T, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 2010; 56:486.</a></li><li class="breakAll">Quest Diagnostics. 2011 eGFR equation update. http://www.wpakidneysupport.org/documents/Quest%20Estimated%20Glomerular%20Filtration%20Rate.pdf (Accessed on September 25, 2011).</li><li><a class="nounderline abstract_t">Rule AD, Teo BW. GFR estimation in Japan and China: what accounts for the difference? Am J Kidney Dis 2009; 53:932.</a></li><li><a class="nounderline abstract_t">Teo BW, Xu H, Wang D, et al. GFR estimating equations in a multiethnic Asian population. Am J Kidney Dis 2011; 58:56.</a></li><li><a class="nounderline abstract_t">Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J Am Soc Nephrol 2021; 32:2994.</a></li><li><a class="nounderline abstract_t">Shlipak MG, Matsushita K, Ärnlöv J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013; 369:932.</a></li><li><a class="nounderline abstract_t">Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51:395.</a></li><li><a class="nounderline abstract_t">Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352:2049.</a></li><li><a class="nounderline abstract_t">Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 2009; 75:652.</a></li><li><a class="nounderline abstract_t">Inker LA, Eckfeldt J, Levey AS, et al. Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. Am J Kidney Dis 2011; 58:682.</a></li><li><a class="nounderline abstract_t">Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011; 22:147.</a></li><li><a class="nounderline abstract_t">Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011; 305:1545.</a></li><li><a class="nounderline abstract_t">Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006; 52:5.</a></li><li><a class="nounderline abstract_t">Brook MO, Bottomley MJ, Mevada C, et al. Repeat testing is essential when estimating chronic kidney disease prevalence and associated cardiovascular risk. QJM 2012; 105:247.</a></li><li><a class="nounderline abstract_t">Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1.</a></li><li><a class="nounderline abstract_t">Coresh J, Astor BC, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002; 39:920.</a></li><li><a class="nounderline abstract_t">Weiner DE, Krassilnikova M, Tighiouart H, et al. CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: a cohort study. BMC Nephrol 2009; 10:26.</a></li><li><a class="nounderline abstract_t">Inker LA, Grams ME, Levey AS, et al. Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. Am J Kidney Dis 2019; 73:206.</a></li><li><a class="nounderline abstract_t">Tonelli M, Muntner P, Lloyd A, et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med 2011; 154:12.</a></li><li><a class="nounderline abstract_t">Levey AS, Schoolwerth AC, Burrows NR, et al. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis 2009; 53:522.</a></li><li><a class="nounderline abstract_t">Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72:247.</a></li><li><a class="nounderline abstract_t">Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int 2015; 88:950.</a></li><li><a class="nounderline abstract_t">Thomas B, Matsushita K, Abate KH, et al. Global Cardiovascular and Renal Outcomes of Reduced GFR. J Am Soc Nephrol 2017; 28:2167.</a></li><li><a class="nounderline abstract_t">Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298:2038.</a></li><li><a class="nounderline abstract_t">Wetzels JF, Kiemeney LA, Swinkels DW, et al. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int 2007; 72:632.</a></li><li><a class="nounderline abstract_t">Darmady EM, Offer J, Woodhouse MA. The parameters of the ageing kidney. J Pathol 1973; 109:195.</a></li><li><a class="nounderline abstract_t">Levey AS, Inker LA, Coresh J. Chronic Kidney Disease in Older People. JAMA 2015; 314:557.</a></li><li><a class="nounderline abstract_t">Glassock R, Delanaye P, El Nahas M. An Age-Calibrated Classification of Chronic Kidney Disease. JAMA 2015; 314:559.</a></li><li><a class="nounderline abstract_t">Delanaye P, Jager KJ, Bökenkamp A, et al. CKD: A Call for an Age-Adapted Definition. J Am Soc Nephrol 2019; 30:1785.</a></li><li><a class="nounderline abstract_t">Glassock RJ, Delanaye P, Rule AD. Should the definition of CKD be changed to include age-adapted GFR criteria? YES. Kidney Int 2020; 97:34.</a></li><li><a class="nounderline abstract_t">Coresh J, Gansevoort RT, CKD Prognosis Consortium, et al. Current CKD Definition Takes into Account Both Relative and Absolute Risk. J Am Soc Nephrol 2020; 31:447.</a></li><li><a class="nounderline abstract_t">Levey AS, Inker LA, Coresh J. "Should the definition of CKD be changed to include age-adapted GFR criteria?": Con: the evaluation and management of CKD, not the definition, should be age-adapted. Kidney Int 2020; 97:37.</a></li><li><a class="nounderline abstract_t">Levey AS, Grams ME, Inker LI. Uses of GFR and Albuminuria Level in Acute and Chronic Kidney Disease. N Engl J Med 2022.</a></li><li><a class="nounderline abstract_t">Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011; 305:1553.</a></li><li><a class="nounderline abstract_t">Tangri N, Grams ME, Levey AS, et al. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. JAMA 2016; 315:164.</a></li><li><a class="nounderline abstract_t">Grams ME, Sang Y, Ballew SH, et al. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int 2018; 93:1442.</a></li><li class="breakAll">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1. http://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm (Accessed on August 29, 2014).</li><li><a class="nounderline abstract_t">Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1.</a></li><li class="breakAll">Caring for Australasians with Renal Impairment (CARI). Dialysis Guidelines. Acceptance onto Dialysis. Timing of referral of chronic kidney disease patients to nephrology services (adult), 2010. http://www.cari.org.au/dialysis_accept_published.php (Accessed on October 27, 2010).</li><li class="breakAll">National Institute for Health and Clinical Excellence (NICE) National Collaborating Centre for Chronic Conditions. Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care, 2008. http://www.nice.org.uk/nicemedia/live/12069/42119/42119.pdf (Accessed on October 07, 2010).</li><li><a class="nounderline abstract_t">Vanholder R, Royal College of Physicians, Renal Association. Chronic kidney disease in adults--UK guidelines for identification, management and referral. Nephrol Dial Transplant 2006; 21:1776.</a></li><li><a class="nounderline abstract_t">Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 2002; 137:479.</a></li><li><a class="nounderline abstract_t">Jungers P, Massy ZA, Nguyen-Khoa T, et al. Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. Nephrol Dial Transplant 2001; 16:2357.</a></li><li><a class="nounderline abstract_t">Avorn J, Winkelmayer WC, Bohn RL, et al. Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol 2002; 55:711.</a></li><li><a class="nounderline abstract_t">Astor BC, Eustace JA, Powe NR, et al. Timing of nephrologist referral and arteriovenous access use: the CHOICE Study. Am J Kidney Dis 2001; 38:494.</a></li></ol></div><div id="topicVersionRevision">Topic 16406 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12859163" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15882252" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19231760" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Conceptual model of CKD: applications and implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18922986" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chronic kidney disease in the United States: a public policy imperative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385419" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Staging of chronic kidney disease: time for a course correction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20686930" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Is the presence of microalbuminuria a relevant marker of kidney disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21840587" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20382326" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Early recognition and prevention of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19242501" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dissecting and refining the staging of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19406541" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Definition and classification of CKD: the debate should be about patient prognosis--a position statement from KDOQI and KDIGO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21150873" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21289598" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307840" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21289597" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20483451" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385668" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The risk of acute renal failure in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21094997" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246142" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : CKD as an underrecognized threat to patient safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447535" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : CKD and risk of hospitalization and death with pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17554148" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19559169" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018975" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chapter 1: Definition and classification of CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16453013" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520612" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19028824" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Current issues in measurement and reporting of urinary albumin excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32024663" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Estimating Urine Albumin-to-Creatinine Ratio from Protein-to-Creatinine Ratio: Development of Equations using Same-Day Measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32658569" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis : An Individual Participant-Based Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11912263" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8793803" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7246778" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7246778" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760447" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Assessing kidney function--measured and estimated glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29499890" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Estimated Glomerular Filtration Rate; Laboratory Implementation and Current Global Status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19436331" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20332400" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23111824" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Age and association of kidney measures with mortality and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22034504" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23360717" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24522492" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23013600" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23013602" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833901" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Measured GFR as a confirmatory test for estimated GFR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32393465" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Kidney Disease, Race, and GFR Estimation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855641" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Evaluation of the modification of diet in renal disease study equation in a large diverse population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22312131" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414839" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A new equation to estimate glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20557989" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20557989" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463761" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : GFR estimation in Japan and China: what accounts for the difference?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21601325" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : GFR estimating equations in a multiethnic Asian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34556489" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24004120" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cystatin C versus creatinine in determining risk based on kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18295055" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15901858" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cystatin C and the risk of death and cardiovascular events among elderly persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19119287" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Factors other than glomerular filtration rate affect serum cystatin C levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855190" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21164029" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cystatin C identifies chronic kidney disease patients at higher risk for complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482744" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16332993" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21964723" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Repeat testing is essential when estimating chronic kidney disease prevalence and associated cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12500213" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11979335" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19761597" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30348535" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21200034" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19231739" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17568785" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26221752" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28408440" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Global Cardiovascular and Renal Outcomes of Reduced GFR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986697" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Prevalence of chronic kidney disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17568781" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4719771" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The parameters of the ageing kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26023868" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Chronic Kidney Disease in Older People.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26023760" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : An Age-Calibrated Classification of Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31506289" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : CKD: A Call for an Age-Adapted Definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31901354" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Should the definition of CKD be changed to include age-adapted GFR criteria? YES.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31871274" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Current CKD Definition Takes into Account Both Relative and Absolute Risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31901355" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : "Should the definition of CKD be changed to include age-adapted GFR criteria?": Con: the evaluation and management of CKD, not the definition, should be age-adapted.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Uses of GFR and Albuminuria Level in Acute and Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482743" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A predictive model for progression of chronic kidney disease to kidney failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26757465" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29605094" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29605094" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114537" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114537" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114537" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16798794" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Chronic kidney disease in adults--UK guidelines for identification, management and referral.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12230348" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The timing of specialist evaluation in chronic kidney disease and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11733627" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12160919" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11532680" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Timing of nephrologist referral and arteriovenous access use: the CHOICE Study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
